French AKI Registry (FAKIR): A Multicenter Study on the In-Hospital Management and Outcomes of Severe Acute Kidney Injury in Nephrology Units

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity Hospital, Strasbourg, France

About this trial

Acute Kidney Injury (AKI) is a common and serious condition in hospitalized patients, especially when it reaches stages 2 or 3 according to the KDIGO classification. These severe forms are associated with high mortality, a risk of progression to chronic kidney disease (CKD), and frequent cardiovascular complications. However, current data on how nephrologists manage these patients during hospitalization-and how these practices influence long-term outcomes-are limited and heterogeneous.

The FAKIR study (French AKI Registry) is a prospective, multicenter, non-interventional observational study designed to describe the clinical management of patients admitted to nephrology departments for AKI stage 2 or 3 and to assess their renal and cardiovascular outcomes up to one year. The study hypothesizes that better characterization of in-hospital practices and patient trajectories will help identify predictors of renal recovery, progression to end-stage renal disease, and major cardiovascular events.

Patients will be followed during hospitalization and at 3, 6, and 12 months to assess renal function, mortality, cardiovascular events, and rehospitalizations. This registry aims to provide real-life, multicenter data to support future guidelines and the development of structured post-AKI care pathways.

Eligibility criteria

Qualifiers

Age ≥ 18 years at admission

Hospitalized in a nephrology ward (standard or intensive nephrology care unit)

Diagnosis of acute kidney injury (AKI) stage 2 or 3 according to KDIGO criteria at the time of admission

Availability of follow-up data at 3 months (clinical or laboratory)

Disqualifiers

AKI stage 1 only

AKI acquired outside the nephrology department without subsequent transfer to nephrology

Hospitalized for another reason without documented AKI stage 2 or 3

Refusal or opposition to data reuse for research purposes

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

750 Participants
are grouped into 1 trial group

Locations

This trial has no locations